New daily pill for breast cancer now available through early access program
NCT ID NCT07643831
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This expanded access program provides giredestrant, a daily oral drug, to people with ER-positive, HER2-negative breast cancer (early or advanced) who have limited treatment options. The goal is to offer early access before the drug is commercially available in the US. Participants take one 30 mg pill each day.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
giredestrant (a daily oral drug)
What this could lead to
If successful, this could offer a new treatment option for people with ER+/HER2- breast cancer who have limited alternatives.
What could go wrong
This is an expanded access program, not a formal trial, so data on effectiveness and safety are still being collected. It may not work for everyone and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ER+/HER2- EARLY OR LOCALLY ADVANCED/METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••